PSC 833

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Washington University School of Medicine

Conditions

Breast CancerCancerCarcinoma, Renal CellKidney NeoplasmKidney NeoplasmsLymphomaNeoplasm MetastasisOvarian Cancer

Phase 1

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

CompletedNCT00001302

National Cancer Institute (NCI)Breast Cancer, Kidney Neoplasm, Lymphoma +2

Start: 1992-09-30End: 2002-06-30Target: 80Updated: 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

CompletedNCT00001383

National Cancer Institute (NCI)Breast Cancer, Cancer, Carcinoma, Renal Cell +2

Start: 1994-03-31End: 2001-01-31Target: 52Updated: 2008-03-04

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

CompletedNCT00001570

National Cancer Institute (NCI)Kidney Neoplasms, Neoplasm Metastasis

Start: 1997-02-28End: 2001-01-31Target: 46Updated: 2008-03-04

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

CompletedNCT00003207

Washington University School of MedicineSarcoma, Unspecified Adult Solid Tumor, Protocol Specific

Start: 1998-03-31End: 2002-07-31Updated: 2013-04-12